



State of Colorado

LEGISLATIVE REQUEST FOR INTERIM STUDY COMMITTEE

To: Legislative Council

Requested by: Representative Primavera
With support of: Representatives Ryden and Sias

Re: Request for interim study committee regarding issues related to the continuum of care for cancer

Date: 04/15/2016

Information Required Pursuant to Section 2-3-303.3, C.R.S.

I hereby request that an interim study committee be formed during the interim between the 2016 and 2017 legislative sessions to study issue related to cancer treatment. The interim study committee would be named the "Interim Committee to Study Issues Related to the Continuum of Care for Cancer."

The policy issues to be studied are:

- open and appropriate access to care, including standard or simplified prior authorization; formulary transparency; and discrimination in benefit design;
- clinical pathways;
- clinical trials; including issues related to clinical trials such as minority underrepresentation; geographical hardships; and access to care;
- step therapy;
- therapeutic substitution or non medical switching;
- rulemaking by the Centers for Medicare and Medicaid Services;
- the National Association of Insurance Commissioners model law implementation, including provisions related to network adequacy and continuity of care; and
- palliative care.

The interim study committee would need to meet 4 times to study the issues.

The interim study committee should consist of 6 members of the General Assembly selected as follows:

- 3 members of the Senate, with 2 appointed by the President of the Senate, and 1 appointed by the minority leader of the Senate.
- 3 members of the House of Representatives, with 2 appointed by the Speaker of the House of Representatives and 1 appointed by the minority leader of the House of Representatives.

The chair of the committee will be appointed by the Speaker of the House of Representatives and the vice-chair of the committee will be appointed by the President of the Senate.

The appointments must be made by June 1, 2016.

Nonlegislative members will have a role in the interim study committee. The committee will contain two non-legislative members: a representative of health care providers appointed by the President of the Senate and a member of the public who has received treatment for cancer appointed by the Speaker of the House of Representatives. Such members will serve as members of the committee for purposes of committee discussions and activities, but may not receive per diem or reimbursement for expenses and may not vote on legislation recommended by the committee, pursuant to Joint Rule 24A (f).

The interim study committee will need 5 bills to address the issues it studies.

Additional Information Related to the Interim Study Committee Request

The committee may receive information from interested persons, including representatives of palliative care organizations and pharmacy providers.

The committee may travel around the Denver Metro area to tour various health facilities and programs.

Thank you for your consideration of this request.